I. Sympathetic activation is associated with increased IL-6, but not CRP in the absence of obesity: lessons from postural tachycardia syndrome and obesity. Am J Physiol Heart Circ Physiol 309: H2098 -H2107, 2015. First published October 9, 2015; doi:10.1152/ajpheart.00409.2015.-Sympathetic activation is thought to contribute to the inflammatory process associated with obesity, which is characterized by elevated circulating C-reactive protein (hsCRP) and interleukin-6 (IL-6). To evaluate whether sympathetic activation is associated with inflammation in the absence of obesity, we studied patients with postural tachycardia syndrome (POTS), a condition characterized by increased sympathetic tone in otherwise healthy individuals. Compared with 23 lean controls, 43 lean female POTS had greater vascular sympathetic modulation (low-frequency blood pressure variability, LFSBP, 3.2 Ϯ 0.4 vs. 5.5 Ϯ 0.6 mmHg 2 , respectively, P ϭ 0.006), lower cardiac parasympathetic modulation (high-frequency heart rate variability, 1,414 Ϯ 398 vs. 369 Ϯ 66 ms 2 , P ϭ 0.001), and increased serum IL-6 (2.33 Ϯ 0.49 vs. 4.15 Ϯ 0.54 pg/ml, P ϭ 0.011), but this was not associated with increases in hsCRP, which was low in both groups (0.69 Ϯ 0.15 vs. 0.82 Ϯ 0.16 mg/l, P ϭ 0.736). To explore the contribution of adiposity to inflammation, we then compared 13 obese female POTS patients and 17 obese female controls to matched lean counterparts (13 POTS and 11 controls). Compared with lean controls, obese controls had increased LFSBP (3.3 Ϯ 0.5 vs. 7.0 Ϯ 1.1 mmHg 2 ; P ϭ 0.016), IL-6 (2.15 Ϯ 0.58 vs. 3.92 Ϯ 0.43 pg/ml; P ϭ 0.030) and hsCRP (0.69 Ϯ 0.20 vs. 3.47 Ϯ 0.72 mg/l; P ϭ 0.001). Obese and lean POTS had similarly high IL-6 but only obese POTS had increased hsCRP (5.76 Ϯ 1.99 mg/l vs. 0.65 Ϯ 0.26; P Ͻ 0.001). In conclusion, sympathetic activation in POTS is associated with increased IL-6 even in the absence of obesity. The coupling between IL-6 and CRP, however, requires increased adiposity, likely through release of IL-6 by visceral fat. 
NEW & NOTEWORTHY

Sympathetic activation and parasympathetic withdrawal in POTS patients were associated with increased serum IL-6 independently of obesity in POTS. Lean POTS patients had normal plasma hsCRP despite high IL-6, suggesting that the coupling between IL-6 and CRP requires increased adiposity.
Circulating inflammatory markers were similar in POTS patients with and without chronic fatigue syndrome.
OBESITY is a state of chronic low-grade inflammation characterized by increased circulating inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) (11, 14, 34) . Prevailing evidence suggests that this inflammatory state is an important link between obesity and associated comorbidities. Thus increased circulating levels of IL-6 and CRP have been associated with increased risk for diabetes mellitus and cardiovascular disease (43) . Adipose tissue, and in particular visceral fat, is considered an important source of inflammatory mediators in obesity (11) , particularly IL-6, which then acts on the liver to upregulate CRP production (15, 28, 34) . The mechanisms that regulate these inflammatory processes, however, are not fully understood.
The sympathetic nervous system (SNS) activity is augmented in obesity, and central sympathetic outflow is positively correlated with indexes of adiposity, in particular visceral fat (2, 27) . Several studies have demonstrated that the SNS is involved in the regulation of inflammatory mediators from lymphoid and nonlymphoid organs, including adipose tissue (25, 33, 58) . Thus sympathetic activation may play a role in the inflammatory state observed in obesity through its interaction with increased adiposity. A novel approach to investigate this phenomenon would be to study conditions characterized by increased sympathetic activation in the absence of obesity.
Postural tachycardia syndrome (POTS) is a chronic condition characterized by disabling intolerance to upright posture associated with excessive tachycardia (38) , and enhanced sympathetic activity (17, 21, 38) . POTS patients offer a unique model of chronic or recurrent sympathetic activation in otherwise healthy lean subjects. We hypothesized, therefore, even in the absence of obesity, sympathetic activation in POTS will be associated with increased indexes of inflammation; i.e., plasma IL-6 and CRP. To test this hypothesis we compared the autonomic and inflammatory profile of lean POTS patients with lean healthy controls to evaluate the association between sympathetic activation and circulating inflammatory markers in the absence of excess adiposity (protocol 1). In addition, we compared the same parameters in obese POTS patients and obese controls to that of their matched lean counterparts to explore the contribution of increased adiposity to inflammation (protocol 2). Finally, because POTS patients often meet criteria for chronic fatigue syndrome (CFS) (38) , and because CFS has been associated with increased inflammatory markers (13), we determine if the presence of CFS would account for the increase in IL-6 in POTS.
MATERIALS AND METHODS
Protocol 1: Autonomic and Inflammatory Profile in Lean POTS Patients and Lean Healthy Controls
Subjects. We studied 43 lean POTS patients [body mass index (BMI) Ͻ 25 kg/m 2 ] referred to the Vanderbilt University Autonomic Dysfunction Center between June 2007 and June 2011, and 23 age-matched lean healthy controls. Because of the strong female predominance in POTS, only female subjects were included in this cohort. A diagnosis of POTS was based on the following criteria: 1) a history of daily orthostatic symptoms for at least 6 mo; 2) heart rate increase of Ն30 beats/min within the first 10 min of standing; 3) the absence of orthostatic hypotension (defined as a fall in BP Ն 20/10 mmHg); and 4) the absence of conditions that can explain postural tachycardia, such as acute dehydration, prolonged bed rest, or medications (38) . All subjects were at least 18 yr old and all were screened with a comprehensive medical history, physical examination, 12-lead ECG and routine laboratory studies. Highly trained athletes and subjects with abnormal renal function, liver function, hematological disease or systemic illnesses that might affect autonomic function were excluded. Subjects had no history of smoking, alcohol abuse, active or recent infections, rheumatologic diseases, or chronic inflammatory conditions including cancer or heart disease. We also excluded subjects taking statins, corticosteroids, or any medication known to affect autonomic function or inflammatory markers who could not discontinue them before study participation. In addition, we studied 3 patients with congenital absence of norepinephrine [dopamine ␤-hydroxylase (DBH) deficiency] as a comparison group with isolated sympathetic failure. The Vanderbilt University Investigational Review Board approved the present study, and written informed consent was obtained from each subject before initiating the study (http:// www.ClinicalTrials.gov identifier NCT00580619).
Experimental design. POTS patients were admitted to the Vanderbilt General Clinical Research Center and were fed a low-monoamine, caffeine-free diet containing 150 meq of sodium and 70 meq of potassium per day. Medications affecting BP, blood volume, the immune system, and autonomic function, including ␤-blockers, were withheld for Ն5 half-lives before admission. Fludrocortisone was discontinued for Ն5 days. Healthy subjects were studied as outpatients in 2 different occasions (screening and study day), and followed a low-monoamine, caffeine-free diet for Ն3 days before testing. All participants completed autonomic function tests and a posture study. Blood was drawn during the posture study for measurement of catecholamines, plasma renin activity (PRA), aldosterone, cytokines, and high sensitivity C-reactive protein (hsCRP).
Autonomic function tests included the Valsalva maneuver and the cold pressor test as described previously (35) . All tests were performed in the morning, Ն2 h after a light breakfast. BP and HR were obtained using an automated oscillometric sphygmomanometer (Dinamap), finger photoplethysmography (Finometer, FMS; or Nexfin, BMEYE), and continuous ECG. Supine baseline data collected during the Valsalva maneuver were digitized and recorded using a WINDAQ data-acquisition system (14 Bit, 500 Hz; DI220; DATAQ; DI720; DATAQ Instruments, Akron, OH) and processed off-line using custom-written software ("Physiowave") in PV-Wave language (PVWave; Visual Numerics, Boulder, CO), developed by one of the authors (AD). Beat-to-beat values of BP and R-R intervals were digitized and analyzed to determine the power spectra in the lowfrequency (0.04 -0.15 Hz) and high-frequency (0.15-0.40 Hz) range, as described previously (1) .
An orthostatic test was performed with patients fasted, and while they remained supine after an overnight rest, to evaluate hemodynamic and hormonal changes on standing. Participants were instructed to abstain from exercising for Ն24 h prior to testing. An indwelling catheter was placed in an antecubital vein at least 30 min before testing. BP and HR were obtained using an automated sphygmomanometer (Dinamap; GE Medical Systems Information Technologies). Subjects were encouraged to stand as long as possible to a maximum of 30 min. During this period, they were allowed to sit at intervals if presyncopal symptoms developed. Supine and upright blood samples were obtained for measurement of catecholamines, PRA, and aldosterone. Blood samples for cytokines and hsCRP were drawn while subjects were supine.
Evaluation of chronic fatigue syndrome (CFS) in POTS. Chronic fatigue syndrome (CFS) is prevalent in POTS patients (38) . Given that some studies have reported that CFS is associated with increased inflammatory markers (13), we determined whether inflammatory markers were increased in POTS patients with CFS (CFS-POTS) compared with those without CFS (non-CFS-POTS). CFS was evaluated in all patients with POTS by means of detailed history, physical examination, laboratory studies, and standardized questionnaires. Fatigue severity was assessed by a subscale of the Checklist of Individual Strength (CIS) that measures both general and physical fatigue; a score Ͼ36 represents severe fatigue (47, 57) . To fulfill the case definition of CFS, fatigue was defined as severe, unexplained, persistent fatigue present for Ն6 mo that was not mainly a result of exertion, was not substantially relieved by rest, was of new onset (not lifelong), and resulted in a significant reduction in previous levels of activity (16) . CFS was defined according to CDC (Centers for Disease Control and Prevention) criteria (16) , and included a case-defining fatigue associated with at least four of the following ancillary symptoms: impaired short-term memory or concentration, sore throat, tender lymphadenopathy, muscle pain, joint pain, headaches of a new type, sleep disturbance, and postexercise malaise (16) . Patients with exclusionary medical or psychiatric conditions for CFS were not included in the present study (16) . As a result, a patient with an eating disorder, and three other patients with case-defining fatigue but insufficient symptom criteria for CFS (i.e., less than four ancillary symptoms) were not included in the analysis. Among the remaining 39 patients who were enrolled in the study, 25 met CFS criteria (CFS POTS) and the other 14 were classified as non-CFS-POTS.
Laboratory analysis. Plasma norepinephrine was collected in plastic syringes, immediately transferred to chilled vacuum tubes with sodium heparin (BD, Franklin Lakes, NJ), and placed on ice. Plasma was separated by centrifugation at Ϫ4°C and stored at Ϫ80°C in collection tubes with 6% GSH (Sigma) until the assay was performed. Concentrations of norepinephrine were measured by batch alumina extraction followed by high-performance liquid chromatography for separation with electrochemical detection and quantification (24) . PRA was assessed by the conversion of angiotensinogen into angiotensin (ANG I) and expressed as nanograms of ANG I produced per milliliter of plasma per hour. Plasma aldosterone was measured by radioimmunoassay (45) . Serum samples for cytokines were centrifuged at Ϫ4°C for 10 min, and stored at Ϫ80°C until analysis. Serum concentrations of IL-1␤, IL-6, IL-8, IL-10, and tumor necrosis factor (TNF)-␣ were measured using the cytometric bead array multiplex system (CBA assay; BD Biosciences, San Jose, CA), as described previously (48) . Plasma levels of hsCRP were measured using a partial enhanced turbidimetric method by the Vanderbilt University Medical Center Clinical Laboratory.
Protocol 2: Contribution of Increased Adiposity to Inflammation in POTS and Healthy Controls
We assessed the inflammatory profile of overweight or obese (BMI Ն 25 kg/m 2 ) POTS patients (termed as "obese" POTS patients, n ϭ 13) and overweight or obese female healthy subjects ("obese" subjects, n ϭ 17) and compared them to age and sex-matched lean counterparts (13 lean POTS and 11 lean healthy subjects) to explore the contribution of increased adiposity to inflammation. All participants met the inclusion/exclusion criteria described under protocol 1. Supine resting BP, HR, and ECG were obtained for spectral analysis, and blood samples for cytokines and hsCRP as described under protocol 1.
Statistical Methods
Data are presented as means Ϯ SE. Frequency tables were generated for categorical variables. Normal distribution of data was assessed using the Kolmogorov-Smirnov test. Comparisons between lean POTS patients and healthy controls, CFS and non-CFS POTS (protocol 1), and between lean and obese subjects (protocol 2) were analyzed by Student's t-tests if they had normal distribution. Otherwise, a Mann-Whitney U-test was used. The 2 test and Fisher's exact test were used for categorical comparisons of data. DBH deficiency patients were studied as a reference group in protocol 1 and were not included in the statistical analysis due to the small sample size. All the tests were two-tailed, and a P Ͻ 0.05 was considered significant. All of the statistical analyses were performed using the statistical package SPSS for Windows (version 20.0, SPSS).
RESULTS
Protocol 1: Autonomic and Inflammatory Profile in Lean POTS Patients and Lean Healthy Controls
Subject characteristics. There were no significant differences in age, white blood cell count, hematocrit, plasma creatinine or liver function tests between lean POTS and lean controls ( Table 1 ). All POTS patients and controls were Caucasian. BMI was statistically lower in POTS patients compared with controls, but the difference was very small. Twenty-five (58%) POTS patients discontinued ␤-blockers (n ϭ 21) and/or fludrocortisone acetate (n ϭ 15) before admission; the remainder (n ϭ 18) was not taking either drug. Chronic severe fatigue (CIS, fatigue subscale Ͼ36) was reported by the majority of POTS patients (88%, n ϭ 35) compared with none of the controls, but CFS diagnostic criteria was met by 58% (n ϭ 25) of them.
Autonomic testing, power spectral densities, and neurohormonal profile. Supine resting systolic BP and HR were significantly higher in lean POTS patients compared with lean healthy controls ( Table 2) . By definition, all POTS patients had postural tachycardia within the first 10 min of standing, and the majority of them (61%, n ϭ 26) could not complete the 30-min test due to orthostatic symptoms. None of the lean controls met the diagnostic criteria for POTS, but 3 of them developed orthostatic symptoms after prolonged standing, and did not complete the test. The total standing time, therefore, was significantly lower in the POTS group compared with healthy controls. After 10 min standing, the increase in HR in POTS patients was 45 Ϯ 3 beats/min compared with 22 Ϯ 2 beats/ min in control subjects (P Ͻ 0.001). BP increased by a similar magnitude in both groups (4 Ϯ 2 vs. 4 Ϯ 2 mmHg for SBP, and 5 Ϯ 1 vs. 7 Ϯ 3 mmHg for DBP in the POTS and control groups, respectively; P Ͼ 0.05), but POTS patients tended to have higher upright systolic BP levels (P ϭ 0.064, Table 2 ). At the time of maximal orthostatic tolerance, POTS patients had a higher upright diastolic BP (72 Ϯ 2 vs. 67 Ϯ 2 mmHg; P ϭ 0.045) and HR (121 Ϯ 3 vs. 87 Ϯ 3 beats/min; P Ͻ 0.001) compared with that of controls. Upright systolic BP was similar between POTS and control groups (106 Ϯ 2 vs. 102 Ϯ 3 mmHg, respectively; P ϭ 0.237). Thus lean POTS patients showed an exaggerated HR response to orthostatic stress associated with higher supine and upright BP levels.
Compared with lean controls, lean POTS patients had an exaggerated decrease in systolic BP during early phase II of the Valsalva maneuver (Table 2 ). BP recovery from early to late phase II and the systolic BP overshoot during phase IV, however, were greater in lean POTS compared with controls. The HR increase during phase II was also greater in the POTS group. The high-frequency component of heart rate variability (HF RRI ) at supine rest was significantly decreased in POTS patients (Table 2 and Fig. 1A ). Supine resting BP variability in the low-frequency component (LF SBP ), on the other hand, was increased in POTS (Fig. 1A) . Patients with congenital absence of norepinephrine (DBH deficiency), as expected, showed a greatly reduced supine resting LF SBP (0.5 Ϯ 0.1 mmHg 2 ) but a similar HF RRI (2,008 Ϯ 1,377 ms 2 ) compared with control subjects (Fig. 1A) .
Lean POTS patients had significantly higher upright plasma norepinephrine compared with controls (Fig. 1B) . As expected, patients with DBH deficiency had levels of supine and upright plasma norepinephrine within the limits of detection of the assay (23 Ϯ 11 and 29 Ϯ 10 pg/ml, respectively; Fig. 1B ). Supine and upright PRA and aldosterone were increased in POTS patients compared with controls (Table 2) .
Circulating inflammatory markers. Lean POTS patients had significantly higher serum levels of IL-6 compared with lean controls (P ϭ 0.011; Table 2 ). Serum levels of IL-1␤, IL-8, IL-10, and TNF-␣, on the other hand, did not differ between the two groups. Interestingly, plasma hsCRP did not differ between both groups despite the elevated serum levels of IL-6 in the POTS group (P ϭ 0.736; Fig. 1C ). Patients with DBH deficiency showed a trend towards lower serum IL-1␤ (1.26 Ϯ 0.11 pg/ml), IL-6 (1.09 Ϯ 0.29 pg/ml; Fig. 1C) , and TNF-␣ (0.35 Ϯ 0.01 pg/ml) compared with the POTS and control groups, whereas IL-8 (12.38 Ϯ 3.18 pg/ml), IL-10 (2.88 Ϯ 0.39 pg/ml), and plasma hsCRP (0.60 Ϯ 0.23 mg/l; Fig. 1C ) were similar in both groups.
When we compared inflammatory markers between patients with CFS-POTS (n ϭ 25) and non-CFS-POTS (n ϭ 14), we found that both groups had similar serum levels of IL-1␤ (3.06 Ϯ 0.61 vs. 2.21 Ϯ 0.47 pg/ml, respectively; P ϭ 0.936), IL-6 (3.74 Ϯ 0.62 vs. 4.62 Ϯ 1.17 pg/ml, respectively; P ϭ 0.976), IL-8 (8.45 Ϯ 0.91 vs. 8.84 Ϯ 1.28 pg/ml, respectively; P ϭ 0.965), IL-10 (3.67 Ϯ 0.72 vs. 3.37 Ϯ 1.02 pg/ml, respectively; P ϭ 0.441), and TNF-␣ (2.70 Ϯ 1.28 vs. 2.26 Ϯ 0.71 pg/ml, respectively; P ϭ 0.329). Plasma hsCRP tended to be lower in CFS-POTS, but the difference was not significant (0.64 Ϯ 0.13 vs. 1.26 Ϯ 0.40 mg/l for non-CFS-POTS; P ϭ 0.463).
Protocol 2: Contribution of Increased Adiposity to Inflammation in POTS and Healthy Controls
Lean vs. obese healthy subjects. We studied 17 obese (37 Ϯ 2 yr; BMI 34.9 Ϯ 1.8 kg/m 2 ) and 11 lean (36 Ϯ 5 yr; BMI 22.4 Ϯ 0.4 kg/m 2 ) healthy female subjects (Table 3) . Eight obese subjects were African-American, and all lean subjects were Caucasian. Supine resting BP was higher in obese subjects compared with lean controls (P Ͻ 0.01), whereas supine HR was similar between groups (P ϭ 0.313). Obese subjects had a significantly greater supine resting LF SBP compared with lean controls (P ϭ 0.016. Fig. 2A ). Both groups, however, had similar supine resting LF RRI , HF RRI (Fig. 2B) , and LF RRI / HF RRI ratio.
Serum IL-6 levels were significantly higher in obese subjects compared with lean controls (P ϭ 0.030. Table 3 and Fig. 2C ). This was accompanied by greater plasma hsCRP in the obese Values are expressed as means Ϯ SE. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LF, low frequency; HF, high frequency; RRI, R-R heart rate interval; IL, interleukin; TNF-␣, tumor necrosis factor-␣; hsCRP, high sensitive C-reactive protein. †HR changes (⌬HR) in the orthostatic stress test are given as the changes between supine and standing at the time of maximal orthostatic tolerance. ‡Blood pressure and heart rate responses are given as the change compared with baseline. §Blood pressure recovery from early to late phase II of the Valsalva maneuver.
group (P ϭ 0.001. Fig. 2D ). IL-6 was positively correlated with both BMI (r ϭ 0.55, P Ͻ 0.01) and LF SBP (r ϭ 0.58; P Ͻ 0.01), whereas CRP was positively correlated only with BMI (r ϭ 0.74, P Ͻ 0.01). No significant differences were found between the obese and lean groups in IL-8, IL-10, and TNF-␣. IL-1␤ tended to be lower in obese subjects, but the difference did not reach significance (P ϭ 0.059).
Lean vs. obese POTS patients. Thirteen obese female patients with POTS (35 Ϯ 3 yr; BMI 30.4 Ϯ 1.0 kg/m 2 ) were studied and compared with 13 age-and sex-matched lean POTS patients (35 Ϯ 1 yr; BMI 21.3 Ϯ 0.4 kg/m 2 , Table 3 ). All POTS patients were Caucasian. Obese POTS patients had higher supine resting BP and LF SBP ( Fig. 2A) compared with the lean group, but only the DBP reached statistical significance (P ϭ 0.036). No significant differences were found between the obese and lean POTS groups in supine HR, LF RRI , HF RRI (Fig. 2B) , and LF RRI /HF RRI ratio.
Plasma hsCRP was significantly greater in obese POTS patients compared with the lean group (P Ͻ 0.001; Table 3 and Fig. 2D ). There were no significant differences between groups in IL-1␤, IL-6 (Fig. 2C) , IL-8, IL-10, and TNF-␣, although IL-6 tended to be higher in the obese group. We did not find any correlation between IL-6 and BMI, given that IL-6 was also elevated in lean POTS patients. We also found that IL-6 did not correlate with LF SBP ; this is likely due to the interindividual heterogeneity of sympathetic activation in POTS and the fact that, in our cohort, both LF SBP and IL-6 were elevated in POTS and were not statistically different between lean and obese groups. CRP, on the other hand, was positively correlated with BMI (r ϭ 0.74, P Ͻ 0.01).
DISCUSSION
The main findings from this study are that 1) lean POTS patients, compared with lean healthy subjects, had higher markers of sympathetic activity (increased supine resting LF SBP and higher upright plasma norepinephrine), suppressed cardiac parasympathetic tone (lower HF RRI ), and increased serum IL-6 levels but normal plasma hsCRP; 2) POTS patients who met CFS criteria had similar serum levels of cytokines and plasma hsCRP compared with those who did not; 3) as expected, obese control subjects had increased resting sympathetic activity (higher LF SBP ) and increased levels of both serum IL-6 and plasma hsCRP compared with their lean counterparts; and 4) both lean and obese POTS patients had elevated IL-6 levels but only obese POTS had increased plasma hsCRP. We propose that sympathetic activation and/or parasympathetic withdrawal are associated with increased serum IL-6 levels in patients with POTS even in the absence of excess weight. Our findings that hsCRP was only elevated in POTS with excess weight and not in lean POTS despite having similarly high IL-6 levels suggest that circulating IL-6 by itself is not enough to induce CRP, and that in POTS, the "coupling" between circulating levels of IL-6 and CRP requires increased adiposity. These results support the concept that inflammation at the level of adipose tissue, primarily in visceral fat, contributes to the upregulation of CRP production.
The SNS is known to modulate inflammatory responses. Stimulation of ␣ 2 -adrenoceptors upregulates the production of proinflammatory cytokines by macrophages (53) , while ␤-adrenergic stimulation increases IL-6 production by human adipocytes and endothelial cells (26, 33) . It has been proposed, therefore, that chronic sympathetic activation contributes to the systemic inflammation observed in obesity. Patients with POTS offer a unique model to determine whether sympathetic activation is associated with inflammation in otherwise healthy subjects, and in the absence of increased adiposity.
We found that lean POTS patients had higher markers of sympathetic activity. Even at supine rest, BP and LF SBP were higher in lean POTS. Even though there is no universal , and serum levels of IL-6 and plasma high sensitivity C-reactive protein (hsCRP) (C) in dopamine ␤-hydroxylase (D␤H) deficiency patients, lean healthy subjects, and lean postural tachycardia syndrome (POTS) patients. D␤H deficiency patients were included as a reference group for isolated sympathetic failure and were not included in the comparisons. Values are expressed as means Ϯ SE. The P values were generated by Mann-Whitney U-test. agreement as to whether LF SBP reflects sympathetic modulation of vascular tone (18, 39, 40, 49) , we have previously shown that LF SBP is increased in obese hypertensives (19, 20, 52) , decreased in patients with pure autonomic failure, virtually abolished by autonomic ganglionic blockade (10, 20, 52) , and was also greatly reduced in the patients with DBH deficiency included in this study. Furthermore, during orthostatic stress and the Valsalva maneuver, lean POTS had excessive HR responses, and higher BP and upright plasma norepinephrine levels, indicating recurrent episodes of excessive sympathetic activation whenever patients stood. In addition, supine HR and the LF RRI /HF RRI ratio were increased in POTS, while HF RRI was decreased, suggesting a shift of the resting cardiac autonomic modulation toward sympathetic predominance and vagal withdrawal. Taken together, our findings indicate the presence of a hyperadrenergic condition in lean females with POTS particularly while upright. This is in agreement with other studies (17, 21, 29, 38, 44) , and our previous observations that POTS patients have an exaggerated decrease in BP induced by ganglionic blockade (30) , and that the orthostatic tachycardia is responsive to ␤-blockade (4, 46) . We recognize that POTS is heterogeneous in presentation and pathophysiological mechanisms. In some patients sympathetic activation is thought to be the primary event ("hyperadrenergic" POTS), whereas in others it is thought to be secondary to a decrease in volume or regional denervation in lower limbs ("neuropathic" POTS) (29, 32, 44) . To complicate things further, there are no agreed-on criteria to characterize these two putative subgroups, or if they are distinct entities or a continuum in a spectrum of disease. Given this heterogeneity, it is likely that sympathetic activation is not distributed homogeneously to all vascular beds (29) . This probably explains why direct measurements of sympathetic nerve activity directed to muscle vasculature (MSNA) during orthostatic challenge were found to be increased in some (36), but not in other studies (17) .
In the context of this increased sympathetic activity, we found that lean POTS patients had elevated levels of circulating IL-6 compared with lean controls, and as high as those found in obese controls. Previous studies have shown that acute sympathetic activation can increase circulating IL-6 levels in lean and obese healthy subjects, for example with mental stress or through ␤-adrenergic stimulation with isoproterenol (25, 54) . Conversely, we found that IL-6 levels were low in our patients with congenital absence of norepinephrine due to DBH deficiency. Taken together, these observations suggest that the SNS upregulates circulating IL-6 levels. Of interest, increased IL-6 may act in the central nervous system to induce sympathetic activation (55, 59) , raising the possibility of a positive feedback loop between the SNS and this inflammatory cytokine. We found group correlations between sympathetic activity, BMI, and inflammatory markers (Fig. 3) ; individual correlations between these parameters, however, were not significant, likely reflecting the heterogeneity in POTS.
Decreased vagal tone, on the other hand, has also been associated with elevated levels of IL-6 in patients with congestive heart failure and the metabolic syndrome (5, 8) . A possible explanation of this association may be an impaired "cholinergic anti-inflammatory pathway" (56) . Thus the suppressed cardiovagal function found in our POTS patients could also contribute to their inflammatory phenotype. Future studies are needed to elucidate the individual contribution of the sympathetic and parasympathetic nervous system to the increased circulating levels of IL-6 in POTS. Finally, when we compared the inflammatory profile of POTS patients who met CFS criteria with those who did not, we found no differences in inflammatory markers between groups. We propose, therefore, that increased IL-6 in POTS was due to sympathetic activation and/or parasympathetic withdrawal rather than to other pathophysiological mechanisms unique to CFS.
We did not find consistent elevations of other circulating cytokines in our POTS or in obese controls, even though adrenergic stimulation has been shown to increase TNF-␣ and IL-1␤ expression (6, 53) . This may be explained by the fact that, unlike IL-6, which is an endocrine cytokine, TNF-␣ and IL-1␤ mainly work locally in an autocrine or paracrine fashion. Hence, their local expression may not always be reflected in enhanced systemic levels (42) .
Circulating IL-6 levels were elevated in our lean POTS patients to the same extent as that of obese controls (Fig. 2) . Adipose tissue is considered one of the main sources of inflammatory mediators in obesity (11) . Up to 35% of circulating IL-6 is secreted from adipocytes (34), and is preferentially secreted from visceral adipose tissue at a rate 2-3 times that of subcutaneous fat (15) . Furthermore, studies in isolated adipocytes have shown that adrenoreceptor stimulation with norepinephrine and isoproterenol increases IL-6 secretion (33, 58), while isoproterenol infusion in lean and obese subjects increases circulating IL-6 (25, 33) . Hence, our findings support the notion that sympathetic activation of adipose tissue contributes to the elevated circulating IL-6 in obesity (27, 33) . From our results we cannot determine the source of the elevated IL-6 in our lean POTS patients. Muscle is an important source of IL-6, mostly during exercise (41), but our levels were taken with patients supine at rest.
Despite having similarly high IL-6 levels, plasma hsCRP was only increased in obese, but not in lean POTS. This finding was unexpected because IL-6 is one of the main inducers of the hepatic production of CRP (28) . We propose that this "uncoupling" between IL-6 and CRP in lean patients with POTS may be explained by differences in the source of IL-6. The portal vein, which drains visceral fat, is the major source of blood supply to the liver (50) . Given that circulating IL-6 levels were similar in lean and obese females with POTS, it is possible that direct drainage of IL-6 from visceral fat to the liver is required to induce CRP production. This is supported by the observation that plasma IL-6 in the portal circulation was 50% greater than in the radial artery of obese subjects, and that it was positively correlated with systemic CRP (14) . Thus we speculate that the source of IL-6 secretion in lean POTS is not visceral fat, and that hepatic production of CRP requires increased visceral adiposity. Further research is needed to test this hypothesis. We cannot exclude, however, an extrahepatic source of CRP in obese subjects. Anty et al. (3) has shown increased IL-6- dependent expression of CRP in adipose tissue from severely obese subjects.
Limitations
A limitation of this study is that its cross-sectional design precludes us from inferring a causal relation between autonomic activity and IL-6. Although BMI strongly correlates with direct measures of adiposity such as total body fat, visceral adipose tissue, and subcutaneous adipose tissue (7, 9, 31, 51) , factors such as age, sex, and lean mass can influence the relationship between BMI and adiposity (9, 22, 51) . We minimized the confounding effect of these factors in the present study; both patients and controls were matched by age and sex, and all our subjects were sedentary. Nonetheless, more accurate assessment of body composition and fat distribution would have been ideal. In ancillary studies, however, we found that plasma leptin was similar between lean POTS and lean controls (17.1 and 14.7 ng/ml) and between overweight/obese POTS and overweight/obese controls (36.5 and 31.5 ng/ml). Furthermore, POTS patients and controls had a similar strong correlation between BMI and plasma leptin (r ϭ 0.71 and r ϭ 0.84, respectively) suggesting that the relationship between BMI and adiposity is preserved in POTS.
We excluded severely deconditioned POTS patients from our studies. This was verified with measurements of peak oxygen consumption (V O 2 max ) during maximal exercise testing on a semirecumbent bicycle performed in a subset of POTS patients (23 lean and 6 obese). Exercise capacity was within normal range in the majority of lean POTS (70%) and all the obese POTS patients, indicating that our patients were not deconditioned. Furthermore, there were no differences in IL-6 or CRP in lean patients that were deconditioned or not. Nonetheless, more detailed measurements of physical activity would have been preferable.
Our conclusions are based only on female subjects given the strong female predominance in POTS. We cannot exclude significant sex differences and therefore we cannot extrapolate our results to male subjects. Although female sexual hormones (i.e., estrogen and progesterone) affect the levels of circulating cytokines, circulating IL-6 does not vary significantly across the menstrual cycle (37) . Plasma CRP, on the other hand, slightly decreases during the follicular phase (Ϫ24 -29%) and it slightly increases during the luteal phase (19 -23%) and menses (17%) (23, 60) . The magnitude of these hormonerelated changes in CRP levels, however, is relatively small and it is unlikely that it accounts for the differences between lean and obese POTS observed in our study (886% difference). Finally, given the heterogeneity of POTS and the relatively small number of patients and controls included in protocol 2, we cannot exclude a type II error for differences between lean and obese groups.
Clinical Significance
Obesity-associated low-grade inflammation may trigger a cascade of pathophysiological processes that lead to complications such as hypertension, atherosclerosis, dyslipidemia, insulin resistance, and diabetes mellitus. Our findings suggest that chronic sympathetic activation and parasympathetic withdrawal are associated with increased serum IL-6 independently of obesity. Plasma hsCRP, on the other hand, was normal in lean POTS despite increased IL-6, suggesting that the coupling between IL-6 and CRP requires increased adiposity. These observations provide evidence of the individual contribution of the autonomic nervous system and excess adiposity to systemic inflammation in POTS and healthy subjects. Future studies are needed to elucidate the specific contribution of the sympathetic and parasympathetic nervous system to inflammation, and to determine whether interventions that restore autonomic balance are useful targets for intervention in this condition.
Circulating proinflammatory cytokines may act centrally to increase sympathetic drive (55, 59) , and to induce behavioral changes such as depression, hyperalgesia, sleep disturbances, and cognitive impairment ("sickness response") (12) . Thus elevated serum IL-6 levels may play a role in the pathophysiology of POTS and CFS.
